Description
Crizonix (Crizotinib) 250mg Online
Crizotinib is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS 1 positive. Crizotinib is the first FDA-approved biomarker-driven therapy for both ALK-positive and ROS1-positive metastatic NSCLC. It is the only FDA-approved drug for ROS 1 positive NSCLC.
Crizonix is indicated for the first-line treatment of adults with ALK-positive advanced NSCLC (non-small cell lung cancer) and for the treatment of adults with previously treated ALK-positive advanced NSCLC & ROS1 (+) NSCLC. Crizotinib is an ALK and ROS1 (c-ros oncogene 1, receptor tyrosine kinase) inhibitor.
Advances in genetic research have shown that Non-Small Cell Lung Cancer (NSCLC) is not a disease, but many cancers with specific genetic differences. Because of these small but important differences, it is possible to develop lung cancer drugs targeting specific genes, such as ANAPlastic lymphoma kinase (ALK). Everyone has the ALK gene in their cells. When a part of it breaks down and collects in the wrong way, it becomes an abnormal ALK gene. This can cause cells to multiply out of control and cause a type of lung cancer to grow. This type of lung cancer is called ALK-positive (ALK) NSCLC.
Crizotinib treats ALK NSCLC that has spread to other parts of the body. By blocking the activity of abnormal ALK genes, Crizotinib can shrink or slow down the growth of tumors. Like ROS-1 produces a protein called ROS, found in the human cell membrane. The ROS protein plays an important role in cell growth and cell specificity. Abnormalities in the ROS-1 gene can lead to a type of lung cancer called non-small cell lung cancer (NSCLC). About 1% to 2% of patients with NSCLC have abnormalities, in which the ROS-1 gene is associated with parts of another gene. The so-called “ROS-1 translocation” is more common in lung cancer patients who are non-smokers and relatively young (average age of 50 years).
In normal cells, the ROS-1 gene creates a protein that regulates cell growth and division. When the ROS-1 gene combines with another gene, the altered DNA sequence creates an abnormal protein that can cause uncontrolled cell growth, leading to the development of cancer. The ROS protein and a protein called ALK have the same structure and function.
